Abstract
Carbamazepine is widely used for the treatment of epilepsy, trigeminal neuralgia and psychiatric disorders. However, therapy is often ineffective, and some patients experience adverse drug reactions, which negatively affect both the efficacy and safety of therapy.
This review systematized and presented up-to-date information regarding the pharmacokinetics and pharmacogenetics of carbamazepine, as well as the most common adverse drug reactions arising from its use. Knowledge of the pharmacokinetics, pharmacodynamics and pharmacogenetics of carbamazepine is necessary to assess the effect of genetically determined activity of cytochrome P450 isoenzymes on the efficacy and safety of this drug. This will make it possible to develop approaches to personalizing the selection of an effective and safe dose of therapy in patients based on individual clinical and biological parameters.
Subject
Applied Mathematics,General Mathematics
Reference76 articles.
1. Pathways of Carbamazepine Bioactivation in Vitro. III. The Role of Human Cytochrome P450 Enzymes in the Formation of 2,3-Dihydroxycarbamazepine
2. Schindler W., Häfliger F. Über Derivate des Iminodibenzyls. Helvetica Chimica Acta. 1954;37(2):472–483. (In Germ.)
3. Kremets KG. Carbamazepine for treatment of alcohol withdrawal. Mezhdunarodnyi nevrologicheskii zhurnal. 2012;(2(48)):163–166. (In Russ.)
4. Pharmacogenetics of carbamazepine
5. Nechaev MO, Sychev DA, Zastrozhin MS, et al. Pharmacogenetic aspects of efficacy and safety profile of carbamazepine (review). Narcology. 2019;18(4):68–82. (In Russ.)